1. Academic Validation
  2. Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation

Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation

  • Eur J Pharmacol. 2014 Nov 15;743:106-16. doi: 10.1016/j.ejphar.2014.09.021.
Malgorzata A Gil 1 Michael Caniga 1 Janice D Woodhouse 1 Joseph Eckman 1 Hyun-Hee Lee 2 Michael Salmon 2 John Naber 3 Valerie T Hamilton 4 Raquel S Sevilla 5 Kimberly Bettano 6 Joel Klappenbach 6 Lily Moy 1 Craig C Correll 2 Francois G Gervais 6 Phieng Siliphaivanh 7 Weisheng Zhang 5 Jie Zhang-Hoover 1 Robbie L McLeod 1 Milenko Cicmil 8
Affiliations

Affiliations

  • 1 Pharmacology, Merck Research Laboratories, Boston, MA 02115, USA.
  • 2 Biology Discovery, Merck Research Laboratories, Boston, MA 02115, USA.
  • 3 Discovery Pharmaceutical Sciences, Merck Research Laboratories, Boston, MA 02115 , USA.
  • 4 Safety Assessment and Laboratory Animal Sciences, Merck Research Laboratories, West Point, PA 19486, USA.
  • 5 Imaging, Merck Research Laboratories, Boston, MA 02115, USA.
  • 6 Target & Pathway Biology, Merck Research Laboratories, Boston, MA 02115, USA.
  • 7 Discovery Chemistry, Merck Research Laboratories, Boston, MA 02115, USA.
  • 8 Pharmacology, Merck Research Laboratories, Boston, MA 02115, USA. Electronic address: [email protected].
Abstract

Alternaria alternata is a Fungal allergen linked to the development of severe asthma in humans. In view of the clinical relationship between A. alternata and asthma, we sought to investigate the allergic activity of this antigen after direct application to the lungs of Brown Norway rats. Here we demonstrate that a single intratracheal instillation of A. alternata induces dose and time dependent eosinophil influx, edema and Type 2 helper cell cytokine production in the lungs of BN rats. We established the temporal profile of eosinophilic infiltration and cytokine production, such as Interleukin-5 and Interleukin-13, following A. alternata challenge. These responses were comparable to Ovalbumin induced models of asthma and resulted in peak inflammatory responses 48h following a single challenge, eliminating the need for multiple sensitizations and challenges. The initial perivascular and peribronchiolar inflammation preceded alveolar inflammation, progressing to a more sub-acute inflammatory response with notable epithelial cell hypertrophy. To limit the effects of an A. alternata inflammatory response, MK-7246 was utilized as it is an antagonist for Chemoattractant Receptor-homologous molecule expressed in Th2 cells. In a dose-dependent manner, MK-7246 decreased eosinophil influx and Th2 cytokine production following the A. alternata challenge. Furthermore, therapeutic administration of corticosteroids resulted in a dose-dependent decrease in eosinophil influx and Th2 cytokine production. Reproducible asthma-related outcomes and amenability to pharmacological intervention by mechanisms relevant to asthma demonstrate that an A. alternata induced pulmonary inflammation in BN rats is a valuable preclinical pharmacodynamic in vivo model for evaluating the pharmacological inhibitors of allergic pulmonary inflammation.

Keywords

Alternaria alternata; Brown Norway Rat; CRTH2; MK-7246.

Figures
Products